Navigation Links
Schering-Plough Reports Financial Results for Third Quarter of 2008
Date:10/21/2008

ded in Research and development

(d) Included in Other expense/(income), net

(e) Included in Special and acquisition-related charges

(f) Included in Equity income

SCHERING-PLOUGH CORPORATION

Report for the period ended September 30 (unaudited):

GAAP Net Sales by Key Product

(Dollars in millions) Third Quarter Nine Months

--------------------- -------------------

2008 2007 % 2008 2007 %

---- ---- - ---- ---- -

HUMAN PRESCRIPTION

PHARMACEUTICALS a/ $3,539 $2,291 54% $10,798 $7,209 50%

REMICADE 564 426 32% 1,627 1,193 36%

TEMODAR 273 215 27% 760 627 21%

NASONEX 258 242 6% 876 821 7%

PEGINTRON 235 221 6% 689 672 3%

CLARINEX / AERIUS 176 171 3% 630 625 1%

FOLLISTIM/PUREGON c/ 142 - - 450 - -

NUVARING c/ 118 - - 330 - -

CLARITIN RX 87 83 5% 326 297 10%

INTEGRILIN 84 78 7% 236 241 (2%)

CAELYX 80 64 24% 232 191 22%

ZEMURON c/ 72 - - 202 - -

AVELOX 65 78 (17%) 274 269 2%

REBETOL 63 60 5% 193 206 (6%)

SUBUTEX / SUBOXONE 63 55 15% 178 163 10%

REMERON c/ 61 - - 190 - -

INTRON A 61
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine news :

1. Schering-Plough Announces Transition of Animal Health Leadership
2. Schering-Plough and Merck Announce Withdrawal of Loratadine/Montelukast NDA and Termination of Respiratory Joint Venture
3. Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck
4. Emerging Combination Therapies, Including Drugs from Novartis/Schering-Plough and GlaxoSmithKline/Theravance Will Drive the COPD Drug Market to More Than $11 Billion in 2017
5. Bayer/Schering-Plough/Shionogis Avelox Has Advantages Over Levofloxacin in the Treatment of Community-Acquired Pneumonia
6. Schering-Plough Announces Expanded Stock Retention Guidelines for Senior Management
7. Schering-Plough to Webcast Presentation by CEO Fred Hassan at Lehman Brothers Eleventh Annual Global Healthcare Conference
8. Schering-Plough Promotes Ian Mcinnes to President of Global Supply Chain
9. CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough
10. Lawsuit Filed in Florida Federal Court Over Marketing of Vytorin and Zetia By Merck and Schering-Plough
11. Schering-Plough CEO to Buy $2 Million in Common Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... York, New York (PRWEB) July 30, 2014 ... from uncontrollable brain bleeding has filed a Xarelto lawsuit ... by the blood thinner, Bernstein Liebhard LLP reports. According ... Court for the District of Vermont on July 25th, ... days when he suffered an irreversible brain bleed that ...
(Date:7/30/2014)... 2014 Imprivata ® (NYSE: ... and secure communications solutions for the healthcare industry, ... the most widely selected single sign-on (SSO) solution ... electronic medical records (EMR) systems with a 51 ... percent in the last 12 months), according to ...
(Date:7/30/2014)... Visitors to our region recognize how special it ... protection. Bob Kiesendahl, one of the owners of Woodloch ... Conservancy for donations collected through participation in the Green ... fast, as visitors welcome the opportunity to invest in ... The Kiesendahl family has owned Woodloch Resort for multiple ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Hamilton ... opening of its new Carmel office on July 30th. ... will finally be moving to the state-of-the-art suite, located ... and innovative space will allow for one-on-one patient comfort, ... surgery experience. , Dr. Hamilton’s new office-suite will ...
(Date:7/30/2014)... (HealthDay News) -- Some obese people have a genetic ... in their brains when they see food, researchers report. ... triggers feelings of pleasure and gratification at the sight ... designed to prevent overeating, the scientists suggested. More ... typically caused by a combination of overeating, a ...
Breaking Medicine News(10 mins):Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3Health News:Imprivata Achieves 51 Percent Single Sign-on Market Share Amongst U.S. Hospitals Using McKesson Paragon or Horizon EMR Systems, According to HIMSS Analytics 2Health News:Pocono Mountain Resort Guests Contribute Over $8500 to Protect Land in 6 Short Months 2Health News:Hamilton Facial Plastic Surgery Opens New Carmel Office 2Health News:Gene Mutation May Make Food More Tempting 2
... Health Advocate Christy Turlington Burns will speak at the ... Health meeting at the AAP National Conference & Exhibition ... ET. Ms. Turlington Burns is the founder of Every ... to increase public awareness of and support for improved ...
... developed by the Centers for Disease Control and ... Pediatrics (AAP), will be launched at the 2011 ... Oct. 15-17. "Autism Case Training -- ... on the fundamental components of identifying, diagnosing, and ...
... New research presented this week highlights the ability ... investigate publicly available genomic data to assess biological ... prospective cancer biomarkers for further validation. The unique ... not possible by other methods, from the massive ...
... onset breast tenderness after starting combination hormone therapy may ... women who don,t experience breast tenderness, a study by ... One reason for this may be that their breasts ... was much more pronounced after initiation of estrogen and ...
... Il. -- MRI scanning could become a powerful new ... according to Loyola University Health System cardiologist Binh An ... MRI study of patients who had recently begun taking ... cholesterol drugs significantly reduced the amount of cholesterol in ...
... 14 (HealthDay News) -- One in six cellphones in Britain ... coli, likely because so many people don,t wash their hands ... The findings also suggest that many people lie about their ... of Hygiene & Tropical Medicine and Queen Mary, University of ...
Cached Medicine News:Health News:CDC to launch new autism curriculum at AAP national conference & exhibition 2Health News:Drug safety, efficacy, and potential new cancer biomarker predicted by NextBio 2Health News:Drug safety, efficacy, and potential new cancer biomarker predicted by NextBio 3Health News:Breast tenderness in women getting combo hormone therapy associated with increase in breast density 2Health News:Breast tenderness in women getting combo hormone therapy associated with increase in breast density 3Health News:MRIs could become powerful tools for monitoring cholesteral therapy 2Health News:1 in 6 Cellphones in Britain Contaminated With 'Fecal Matter' 2
(Date:7/30/2014)... ALEXANDRIA, Va. , July 30, 2014 /PRNewswire-USNewswire/ ... of Managed Care Pharmacy (AMCP) last evening expressed ... developed by the Joint Commission of Pharmacy Practitioners ... other member organizations over a two-year period to ... process for pharmacists.  "Pharmacists are ...
(Date:7/30/2014)... 30, 2014 PuraMed BioScience ® , ... over-the-counter (OTC) medicinal and healthcare products, announced today ... name along with the name,s red and yellow ... trademarked name MigraPure ®  going forward. The ... homeopathic, natural migraine pain reliever will be reintroduced ...
(Date:7/30/2014)... -- Research and Markets has announced the addition of ... report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... a lower CAGR in developed countries; however, it is expected to ... , India , and Brazil ... of the hematology analyzers and reagents market is driven by factors ...
Breaking Medicine Technology:AMCP Endorses JCPP "Pharmacists' Patient Care Process" 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3Hematology Analyzers & Reagents Market - Forecasts to 2019 2
... 13, 3010 Amgen (Nasdaq: AMGN ) ... evaluating XGEVA™ (denosumab) versus placebo in 1,432 men with ... study, demonstrated that XGEVA significantly improved median bone metastasis-free ... p=0.03) compared to placebo (primary endpoint), and significantly improved ...
... Fla., Dec. 13, 2010 The creators of the innovative Pill ... toys and a much needed medication management system to pediatric ... at Broward General, in Fort Lauderdale, Florida. ... will be onsite Wednesday, December 15, from 1-3 pm distributing ...
Cached Medicine Technology:XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer 2XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer 3XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer 4XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer 5XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer 6XGEVA™ (Denosumab) Significantly Improved Bone Metastasis-Free Survival in Men With Prostate Cancer 7Med Time Technology, Inc. Teams up with Give A Smile, Inc. to Provide Pill Timer™ Kits and Toys to Children and Parents at the Chris Evert Children's Hospital of Broward General 2
Inquire...
... with low electroendosmosis (EEO) ... DNA/RNA applications. If separated ... be used as substrates ... and restriction endonucleases, a ...
... NuSieve 3:1 Agarose is a molecular biology grade, ... for fine resolution of small DNA, RNA, and ... enhance the speed of gel processing and blotting. ... resolution of DNA fragments up to 1,000 bp, ...
... With a very high gel ... exclusion limit, Certified megabase agarose is ... FIGE applications. The gels remain easy ... as 0.3% and allow shorter run ...
Medicine Products: